ThromboView Phase Ib PE Extension Study

Extension to Phase Ib, multi centre, prospective image acquisition trial of [99mTc]ThromboView, at a dose of 0.5 mg labelled with 685-785 MBq 99mTc, in subjects with a diagnosis of at least one pulmonary embolus at a segmental or more proximal pulmonary artery level by CTPA. Eligible and consenting study subjects will receive a single dose of [99mTc]ThromboView prepared using a two-vial formulation and administered by intravenous injection within 72 hours of having undergone a CTPA scan to determine eligibility. Nuclear Medicine imaging scans (both SPECT and Planar) will be performed at 15 minutes, 2 & 4 hours post injection. 24 hour blood and urine sampling performed to assess Radiopharmacokinetc profile. Subjects return for safety assessments at Days 7, 30 and 90 post-injection.